MLYS Stock Up 125% after 7-Day Win Streak
Mineralys Therapeutics (MLYS) stock hit day 7 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 125% return. The company has gained about $2.7 Bil in value over the last 7 days, with its current market capitalization at about $2.2 Bil. The stock remains 169.0% above its value at the end of 2024. This compares with year-to-date returns of 10.5% for the S&P 500.
MLYS is a clinical-stage biopharmaceutical company developing medicines targeting diseases caused by abnormally elevated aldosterone.
Comparing MLYS Stock Returns With The S&P 500
The following table summarizes the return for MLYS stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | MLYS | S&P 500 |
|---|---|---|
| 1D | 13.2% | 0.8% |
| 7D (Current Streak) | 124.7% | 1.0% |
| 1M (21D) | 147.0% | 3.2% |
| 3M (63D) | 113.4% | 8.9% |
| YTD 2025 | 169.0% | 10.5% |
| 2024 | 43.1% | 23.3% |
| 2023 | 24.2% | |
| 2022 | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 41 S&P constituents with 3 days or more of consecutive gains and 48 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 18 | 30 |
| 4D | 13 | 12 |
| 5D | 5 | 3 |
| 6D | 3 | 1 |
| 7D or more | 2 | 2 |
| Total >=3 D | 41 | 48 |
Key Financials for Mineralys Therapeutics (MLYS)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-84.7 Mil | $-192.4 Mil |
| Net Income | $-71.9 Mil | $-177.8 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-44.4 Mil | $-46.7 Mil |
| Net Income | $-42.2 Mil | $-43.3 Mil |
While MLYS stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.